Dr. John C. ShershowAdult ADHD PsychiatryBook: (212) 265-4310
Menu

By the editorial team of Dr. John C. Shershow, M.D.Published Data: CMS Part D data years 2019 to 2024Download the data (CSV)Summary figures (CSV)Editorial policy

  • +50.7%New York claims for patients 65 and older, 2019 to 2024 (70,327 to 106,006)CMS Part D Prescribers by Geography and Drug, 2019 and 2024
  • +11.6%growth in New York's Medicare beneficiaries aged 65 and older over the same yearsCMS Medicare Monthly Enrollment, annual 2019 and 2024
  • +53.9%New Jersey claims for patients 65 and older (29,779 to 45,815)CMS Part D, 2019 and 2024
  • 45.0%share of New York's ADHD-medication claims that were for patients 65 and older in 2024, up from 39.3% in 2019CMS Part D, 2019 and 2024
  • 235,728ADHD-medication claims from New York prescribers in 2024, all ages (92,383 in New Jersey)CMS Part D, 2024
Claims for patients 65 and older grew much faster than the 65-and-older Medicare population (2019 = 100)
050100150200201920202021202220232024151154112113Index, 2019 = 100
  • New York prescribers: ADHD-medication claims, patients 65+
  • New Jersey prescribers: ADHD-medication claims, patients 65+
  • New York: Medicare beneficiaries 65+
  • New Jersey: Medicare beneficiaries 65+

Sources: CMS Medicare Part D Prescribers by Geography and Drug and CMS Medicare Monthly Enrollment, 2019 to 2024. Each line divides that year's figure by its 2019 figure. Claims include refills; the national series is in the table below.

ADHD-medication claims in Medicare Part D by prescriber's state, 2019 to 2024
YearAll agesAge 65+Under 6565+ sharePart D enrolleesPer 1,000 enrollees
New York
2019178,87570,327108,54839.3%2,840,65563.0
2020191,07476,601114,47340.1%2,905,92765.8
2021196,35181,290115,06141.4%2,965,37066.2
2022208,35787,999120,35842.2%3,038,29868.6
2023217,57794,653122,92443.5%3,119,67369.7
2024235,728106,006129,72245.0%3,235,21672.9
New Jersey
201973,56929,77943,79040.5%1,205,54461.0
202077,81632,03845,77841.2%1,236,04863.0
202180,49734,62845,86943.0%1,268,60463.5
202284,09537,99446,10145.2%1,304,03564.5
202386,57740,15446,42346.4%1,345,64364.3
202492,38345,81546,56849.6%1,407,21665.6
United States
20193,444,1101,328,2282,115,88238.6%45,827,09175.2
20203,640,6871,449,5082,191,17939.8%47,413,12176.8
20213,714,9551,527,5282,187,42741.1%48,818,84976.1
20223,886,3541,645,9022,240,45242.4%50,305,09777.3
20234,038,1661,775,5702,262,59644.0%51,903,54577.8
20244,510,7642,102,1202,408,64446.6%54,375,19883.0

Claims are ADHD-medication claims, all ages and 65 and older. Part D enrollees are people in a Part D plan in the state, in person-years (CMS Medicare Monthly Enrollment). "Per 1,000 enrollees" divides all-ages claims by Part D enrollees; claims are counted by where the prescriber practices, so the rate is an approximation.

Older adults account for most of the growth

Claims written by New York prescribers rose 31.8% overall between 2019 and 2024, from 178,875 to 235,728. Claims for patients 65 and older rose 50.7%; claims for Medicare patients under 65, who qualify through a disability or kidney failure, rose 19.5%. As a result, the 65-and-older share went from 39.3% to 45.0%.

New Jersey followed the same pattern: claims for patients 65 and older rose 53.9% (29,779 to 45,815) and claims for patients under 65 rose 6.3%. Nationally, the 65-and-older figure rose 58.3%.

Part of the rise reflects more people in Medicare. New York's Medicare beneficiaries aged 65 and older grew 11.6% over the period and New Jersey's 13.0%, so claims for older patients grew several times faster than the older Medicare population. Part D enrollment in New York, all ages, grew 13.9%; 65-and-older claims still grew about 3.7 times as fast.

Which medications

Mixed amphetamine salts accounted for 52.5% of New York's ADHD-medication claims in 2024 (123,717 claims). Stimulants made up 89.0% of the total; the non-stimulants in this file (atomoxetine, viloxazine, and extended-release guanfacine and clonidine) made up the rest.

ADHD-medication claims by drug, New York and New Jersey prescribers, 2024
DrugNew YorkNew Jersey
Mixed amphetamine salts (Adderall and generics)123,71753,474
Methylphenidate (Ritalin, Concerta and generics)55,64217,807
Lisdexamfetamine (Vyvanse and generics)20,6267,762
Atomoxetine (Strattera and generics), non-stimulant16,4216,277
Guanfacine extended-release (Intuniv and generics), non-stimulant8,0122,745
Dextroamphetamine (Dexedrine, Zenzedi and generics)4,9971,495
Dexmethylphenidate (Focalin and generics; Azstarys)4,6862,053
Clonidine extended-release (Kapvay and generics), non-stimulant893391
Viloxazine (Qelbree), non-stimulant525175
Amphetamine (Evekeo, Adzenys XR-ODT, Dyanavel XR and generics)209191
Methamphetamine013

Claims for all ages. Brand and generic versions are combined. CMS leaves out brand or generic rows with fewer than 11 claims in a state, so a 0 can mean fewer than 11 claims for each version.

How we counted

Data. CMS Medicare Part D Prescribers by Geography and Drug, data years 2019 to 2024 (one file per year; the 2024 file is dated May 21, 2026 in the CMS data catalog). We used the national row and the state rows for New York and New Jersey. In this file, the state is the one where the prescriber is located as reported in the federal NPI file, not the patient's state.

Drugs. Every brand and generic row with these generic names: dextroamphetamine/amphetamine (mixed amphetamine salts), methylphenidate, lisdexamfetamine, dextroamphetamine, dexmethylphenidate, serdexmethylphenidate/dexmethylphenidate, amphetamine, methamphetamine, atomoxetine and viloxazine. For guanfacine and clonidine, the file lists the extended-release forms approved for ADHD as their own rows (the brands Intuniv and Kapvay, and the brand-name field values Guanfacine Hcl Er and Clonidine Hcl Er), and we included those rows (8,905 New York claims in 2024). Their FDA labels rest on studies in children and teenagers aged 6 to 17, and the Intuniv label says safety and efficacy in patients 65 and older have not been established. The file does not record why a drug was prescribed, so some of these claims may be for other conditions. The immediate-release tablets and the clonidine patch are approved for high blood pressure and are left out.

Claims. Tot_Clms (Part D claims, which include original prescriptions and refills) summed across rows. CMS leaves out any brand-and-generic row with fewer than 11 claims in a state, so state totals can be slightly low. "Age 65+" is GE65_Tot_Clms. CMS hides 65-and-older counts in some small rows (fewer than 11 claims, or hidden so that another small cell cannot be worked out): in New York those rows held at most 149 claims of any age in 2024 and 80 in 2019, so the 65-and-older totals are minimums that may be short by that much, and the under-65 figures (all ages minus 65 and older) may be high by the same amount.

Enrollment. CMS Medicare Monthly Enrollment, yearly rows, which CMS counts in person-years (months enrolled divided by 12): PRSCRPTN_DRUG_TOT_BENES (Part D enrollees) and the sum of the age groups from 65 upward (all Medicare beneficiaries aged 65 and older). Percentages are rounded half up to one decimal.

The comparison. CMS does not publish Part D enrollment by age, so the page compares 65-and-older Part D claims with all Medicare beneficiaries aged 65 and older, including those without a Part D plan. As a check, New York's Part D enrollment for all ages grew 13.9% from 2019 to 2024 (2,840,655 to 3,235,216), so 65-and-older claims (50.7%) still grew about 3.7 times as fast.

Limits

  • Medicare only. Commercial insurance, Medicaid-only coverage and cash payments are not included, and most adults with ADHD are under 65 and not in Medicare.
  • No diagnosis is recorded, so claims cannot be tied to ADHD. Claims count fills, not people: one person filling a prescription every month counts 12 times a year.
  • The state is where the prescriber practices. A New Jersey resident whose psychiatrist practices in Manhattan counts under New York.
  • Several ADHD medications were on the FDA shortage list from late 2022 onward, so claim counts from 2022 to 2024 may reflect supply as well as prescribing. A prescription that could not be filled does not appear in the data.

Sources

  1. CMS, Medicare Part D Prescribers by Geography and Drug. Data years 2019 to 2024.
  2. CMS, Medicare Monthly Enrollment. Yearly person-year figures 2019 to 2024 (release with monthly data through July 2026, updated October 22, 2026).

Cite this study

Dr. John C. Shershow, M.D.. (2026). ADHD medication prescriptions in Medicare: New York and New Jersey, 2019 to 2024. https://drjohnshershow.com/research/adhd-prescriptions-medicare-new-york-new-jersey/

The table behind this page is free to reuse under CC BY 4.0: credit Dr. John C. Shershow, M.D. and link to this page. Download the CSV or the summary figures (CSV).

More research

Looking for an adult ADHD evaluation in New York or New Jersey?

Dr. Shershow evaluates and treats adults with ADHD located in New York or New Jersey. Call the office, or leave your number and the office will call you.

Prefer a call back?

Leave your number and the office will call you to schedule.

No health details needed. Not for emergencies: call or text 988, or call 911.

Book AppointmentCall (212) 265-4310